This systematic review re-analysed 43 modelled scenarios from 21 economic evaluations of liquid biopsy in cancer. Costs were harmonised to 2024 euros, and net monetary benefit was recalculated under eight willingness-to-pay thresholds. Median net benefit was positive under all eight, ranging from €79.52 to €5,091.21 per patient. Under a common threshold of twice Italian GDP per capita, the median was €1,560.07 per patient. Eight scenarios were dominant, while 17 (39.5%) changed classification across thresholds. Scenarios differed in pathways, assumptions and local costs, were not independent, and lacked patient-level data.
Why it is interesting: The same modelled costs and QALYs can look cost-effective or not, depending only on the threshold chosen. Two cost-saving scenarios lowered health, which a positive net benefit alone does not reveal.
Cite this item
BibTeX
Free sign-up. A digest of the new papers twice a week, grouped by domain.